And, of course, we know that Dr. Mullholand is working on his own therapy and trials that is not DCVAX.
>>Looking beyond this trial, Dr Mulholland continued: “Now that we have recruited the 119 patients to the IPI-GLIO trial we have planned a programme of trials so this work can continue. We have established a Glioblastoma Research Group and laboratory at UCL Cancer Institute. We are bringing together the newest drugs from the pharmaceutical industry together with the latest developments in scientific research to try to find a cure for this devastating disease.”
>>A push on getting patients into clinical trials, and more training for young doctors in the disease, the most common form of brain tumour, could pay rapid dividends, he says.
>>There have been few advances in care in decades because patients are being “neglected” by the medical establishment and pharmaceutical industry, Mulholland says bluntly.
The number of patients with glioblastoma, which he sees as an “absolute epidemic, shocking epidemic”, is nonetheless “not enough for a business case” to encourage companies to test their new drugs against the cancer.
Market Data 
Markets 
AI
